These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 8967021)

  • 1. [Fluvastatin in the treatment of hyperlipoproteinemia, initial experience].
    Ceska R
    Vnitr Lek; 1996 Aug; 42(8):533-6. PubMed ID: 8967021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E; Muratti EN; Eliav O; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Simvastatin in the treatment of familial hypercholesterolemia].
    Ceska R; Sobra J; Procházková R; Kvasilová M
    Cas Lek Cesk; 1995 May; 134(10):310-3. PubMed ID: 7788650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
    Plosker GL; Wagstaff AJ
    Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia.
    Tomlinson B; Mak TW; Tsui JY; Woo J; Shek CC; Critchley JA; Masarei JR
    Am J Cardiol; 1995 Jul; 76(2):136A-139A. PubMed ID: 7604789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolaemic women.
    Baggio G; De Candia O; Forte PL; Mello F; Andriolli A; Donazzan S; Valerio G; Milani M; Crepaldi G
    Drugs; 1994; 47 Suppl 2():59-63. PubMed ID: 7517835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.
    Koizumi J; Haraki T; Yagi K; Inazu A; Kajinami K; Miyamoto S; Ueda K; Ohta M; Takegoshi T; Takeda M
    Am J Cardiol; 1995 Jul; 76(2):47A-50A. PubMed ID: 7604797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
    Leitersdorf E; Eisenberg S; Eliav O; Friedlander Y; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Wurm M
    Circulation; 1993 Apr; 87(4 Suppl):III35-44. PubMed ID: 8462179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.
    Kellick KA; Burns K; McAndrew E; Haberl E; Hook N; Ellis A
    Am J Cardiol; 1995 Jul; 76(2):62A-64A. PubMed ID: 7604801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency.
    Lintott CJ; Scott RS; Bremer JM; Shand BI
    Am J Cardiol; 1995 Jul; 76(2):97A-101A. PubMed ID: 7604809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of current clinical findings with fluvastatin.
    Garnett WR
    Am J Cardiol; 1996 Sep; 78(6A):20-5. PubMed ID: 8875971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
    Greten H; Beil FU; Schneider J; Weisweiler P; Armstrong VW; Keller C; Klör HU; von Hodenberg E; Weidinger G; Eskötter H
    Am J Med; 1994 Jun; 96(6A):55S-63S. PubMed ID: 8017468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials.
    Kong SX; Crawford SY; Gandhi SK; Seeger JD; Schumock GT; Lam NP; Stubbings J; Schoen MD
    Clin Ther; 1997; 19(4):778-97. PubMed ID: 9377621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.
    Levy RI; Troendle AJ; Fattu JM
    Circulation; 1993 Apr; 87(4 Suppl):III45-53. PubMed ID: 8462180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
    Zavoral JH; Haggerty BJ; Winick AG; Bergmann SD
    Am J Cardiol; 1995 Jul; 76(2):37A-40A. PubMed ID: 7604795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients.
    Teramoto T; Goto Y; Kurokawa K; Nakamura H; Yoshida S; Saito Y; Nakaya N; Itakura H; Takaku F; Yamada N
    Am J Cardiol; 1995 Jul; 76(2):33A-36A. PubMed ID: 7604794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.